eli lilly tirzepatide fda approval approves Lilly's Zepbound (tirzepatide) for chronic weight management FDA Approves Eli Lilly's Mounjaro

Key Point to Remember: MS = Young women, CNS demyelination, relapsing-remitting neurological deficits, MRI plaques, CSF oligoclonal bands, treated with steroids + disease-modifying agents.

This 0.5 mg dose builds upon the 0.25 mg starting dose to enhance the effectiveness of your weight management program

We expect to establish long-term cooperative relation with various customers around the world and look forward to mutual benefits and shared growth

In patients with obesity (mean age 51.3 years, 65.6% women), semaglutide compared with non-GLP-1RA anti-obesity medications was associated with lower risk for incident CUD in patients with no prior history CUD (HR: 0.56, 95% CI: 0.420.75), and recurrent CUD diagnosis in patients with a prior history CUD (HR: 0.62, 95% CI: 0.460.84)

Drug repurposing was common (22.2%), notably involving semaglutide and liraglutide, originally approved for type 2 diabetes